SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

SNDL Inc.NASDAQ: SNDL

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit dips below year-ago levels

Q1 FY2026 gross profit of CA$52.81M fell 6.8% year over year, behind the +3.3% change in trailing-twelve-month gross profit. Sequentially, it fell 24.8% from the prior quarter. Over 3 fiscal years it compounded at +22.6% a year.

Context

  • Gross profit amounted to 27.3% of revenue in FY2025, up 1.2 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -6.8% toward the trailing-twelve-month pace of +3.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$52.81M-24.8% QoQ
Last fiscal yearDec 2025
CA$258.65M+7.6% YoY
LTMMar 2026
CA$254.82M+3.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.8%——
1 year+7.6%——
3-year CAGR+22.6%——
5-year CAGR——
10-year CAGR——

Gross Profit history

CAD · from the income statement

Latest · FY2025
258.65M CAD
Year-over-year change
+7.6%

Gross Profit vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.3% is the 5th highest of 8, against a peer median of +3.9%.
  • Gross profit amounts to 27.2% of revenue for SNDL, versus a peer median of 65.4%.
SNDL Competitors
Gross Profit for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$361.62M USD+3.9%+7.2%70.4%
EBSEmergent BioSolutions Inc.LTM Mar 2026$300.8M USD-14.5%-9.5%44.4%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$271.85M USD+60.4%+78.1%65.0%
SNDLSNDL Inc.LTM Mar 2026CA$254.82M CAD+3.3%+22.6%27.2%
EOLSEvolus, Inc.LTM Mar 2026$197.81M USD+5.8%+29.0%65.5%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$187.95M USD+39.8%-10.0%80.9%
SIGASIGA Technologies, Inc.LTM Mar 2026$61.29M USD-33.5%-13.5%65.4%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$31.9M USD-14.0%-1.1%63.5%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$55K USD———
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$306K USD———
Peer median (excluding SNDL) —+3.9%-1.1%65.4%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.